Shots:

• The P-II trial investigates the longer interval of intravitreal (IVT) injection of IBI302 (6.4mg, 8mg, Q8W or Q12W based on loading therapy) vs Aflibercept (2mg, Q8W, after loading therapy) in patients (n=132) with neovascular age-related macular degeneration (nAMD)
• The study met the 1EP, showing improved mean BCVA of 10.5 ETDRS letters & 11.0 ETDRS letters vs 9.8 ETDRS letters as well as mean change in CST of -163.19μm & -184.46μm vs -108.23μm from baseline at wk.40
• Furthermore, ~81% & 88% of patients extended the dosing interval to Q12W which was comparable to the results with Aflibercept in the PULSAR study (83%) or Faricimab in TENAYA (79.7%) & LUCERNE (77.8%) studies. The P-III (STAR) study of IBI302 (8mg, Q16W) is anticipated in Oct'23

Ref: Innovent | Image: Innovent

Related News:- Innovent and AnHeart Therapeutics Report the NMPA’s Acceptance of Second NDA for Taletrectinib to Treat Lung Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com